- Global Clinical Study Program Across Dengue Endemic Regions in Latin
America and AsiaLYON, France, Feb. 18 /CNW/ - Sanofi Pasteur, the vaccines division of
sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its
investigational tetravalent dengue vaccine is entering into a pediatric
clinical study in Thailand to assess the efficacy of the vaccine in protecting
children against dengue, the most widespread tropical disease after malaria.
Sanofi Pasteur's tetravalent dengue vaccine candidate is the first to reach
this stage of clinical development.
Sanofi Pasteur is collaborating with Mahidol University of Thailand, the
Ministry of Public Health, and the Pediatric Dengue Vaccine Initiative (PDVI)
to conduct this efficacy study in the province of Ratchaburi.
"Large scale pediatric studies are instrumental for the development of a
safe and efficacious dengue vaccine to protect against a disease that
primarily affects children," said Dr. Pratap Singhasivanon, Dean of the
Faculty of Tropical Medicine, Mahidol University. "We are happy to contribute
to an important milestone with the actual start of an efficacy study in
The Sanofi Pasteur clinical study program follows guidelines from the
Initiative for Vaccine Research (IVR) led by the World Health Organization
(WHO), which fosters the global efforts towards dengue vaccine development.
"WHO is committed to the availability of a dengue vaccine that will
ultimately benefit children in endemic countries," said Dr. Joachim Hombach,
Coordinator Implementation Research for IVR, WHO.
About Sanofi Pasteur dengue vaccine global clinical study program
Sanofi Pasteur started the development of a dengue vaccine in the 90's.
Clinical studies with the most advanced tetravalent candidate vaccine started
in the 2000's. In a study in the United States, immunization with three doses
of Sanofi Pasteur's tetravalent dengue vaccine candidate generated a
sero-neutralizing antibody response against all four serotypes of the virus
responsible for dengue fever in 100 percent of adults who participated in the
trial(1). The Sanofi Pasteur dengue vaccine research program includes ongoing
clinical studies in Mexico, Peru, and The Philippines with adults and
About dengue fever
Dengue fever is a mosquito-borne disease caused by four types of dengue
viruses (type 1 to 4). Overall, the disease is a potential threat for almost
half the world's population. Of the estimated 230 million people infected
annually, two million, mostly children, develop dengue hemorrhagic fever
(DHF), a severe form of the disease(2). DHF is a leading cause of
hospitalization in South-East Asia, placing tremendous pressure on strained
Dengue fever occurs mostly in tropical and subtropical countries and is
spreading to new parts of the globe each year. The WHO has warned that the
Western Pacific Region may be heading for a major dengue outbreak(3).
Outbreaks recently have been observed in Paraguay and the Middle East. In
addition, dengue affects countries such as Australia (Queensland) and the
United States (Puerto Rico, Texas-Mexico border, Hawaii and the US-affiliated
Pacific Islands). A substantial number of people traveling to endemic regions
are also infected each year.
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than 1.6 billion doses of vaccine in 2008, making it possible to immunize
more than 500 million people across the globe. A world leader in the vaccine
industry, Sanofi Pasteur offers the broadest range of vaccines protecting
against 20 infectious diseases. The company's heritage, to create vaccines
that protect life, dates back more than a century. Sanofi Pasteur is the
largest company entirely dedicated to vaccines. Every day, the company invests
more than EUR 1 million in research and development. For more information,
please visit: http://www.sanofipasteur.com
1. Data generated by the WHO Flavivirus Laboratory Reference Center,
Mahidol University, Bangkok, Thailand, presented at the American Society of
Tropical Medicine and Hygiene's (ASTMH) 56th annual meeting held in
Philadelphia, Pennsylvania, USA
2. Pediatric Dengue Vaccine Initiative (PDVI), presentation "Estimating
the global burden of dengue" at 2nd Int Conf on Dengue & DHF, 15-17 Oct 08,
3. WHO alarmed about the spread of dengue,
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include product development, product potential projections and estimates and
their underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future events, operations,
products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects,"
"anticipates," "believes," "intends," "estimates," "plans" and similar
expressions. Although sanofi-aventis' management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the FDA
or the EMEA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could
affect the availability or commercial potential of such products candidates,
the absence of guarantee that the products candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives as well as those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for
the year ended December 31, 2007. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise any
forward-looking information or statements.
For further information: Global Media Relations, Pascal Barollier, T.
+33(0)4-37-37-50-38, firstname.lastname@example.org; US Media Relations:
Len Lavenda, T. (570) 957-4446, email@example.com